Report cover image

In Vivo CRO Market Growth, Size, Trends Analysis - By Model Type, By Modality, By Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published May 15, 2025
Length 250 Pages
SKU # SPER20186981

Description

In Vivo CRO Market Introduction and Overview

According to SPER market research, ‘Global In Vivo CRO Market Size- By Model Type, By Modality, By Indication – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global In Vivo CRO Market is predicted to reach 11.47 billion by 2034 with a CAGR of 8.38%.

In vivo CRO services are a type of research service given by Contract Research Organisations (CROs) that includes tests conducted on living organisms, often animals, to examine the safety and efficacy of innovative medicines. These services frequently involve preclinical investigations, such as toxicology, pharmacokinetics, and efficacy studies, which are used to promote the development and regulatory approval of new medications or medical devices.

Restraints:

The high cost of drug development has hampered market growth. Developing novel medication therapies is an extremely expensive procedure. This includes everything from doing basic research and clinical trials to securing regulatory approval. Pharmaceutical companies are under intense pressure to maximise their return on investment for new treatments. These factors are projected to limit the growth of the in vivo CRO market over the forecast period.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered

By Model Type, By Modality, By Indication

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

IQVIA Inc, Crown Bioscience, Taconic Biosciences, Inc, PsychoGenics Inc, Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc.

Global In Vivo CRO Market Segmentation:

By Model Type: Based on the Model Type, Global In Vivo CRO Market is segmented as; Rodent Based, Non-Rodent Based.

By Modality: Based on the Modality, Global In Vivo CRO Market is segmented as; Small Molecule, Large Molecule.

By Indication: Based on the Indication, Global In Vivo CRO Market is segmented as; Oncology, CNS Conditions, Diabetes, Obesity, Pain management, Autoimmune/inflammation conditions, Others.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

250 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global In Vivo CRO Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global In Vivo CRO Market
7. Global In Vivo CRO Market, By Model Type (USD Million) 2021-2034
7.1. Rodent based
7.1.1. Rat Models
7.1.2. Mice Models
7.1.3. Others
7.2. Non-Rodent based
8. Global In Vivo CRO Market, By Modality (USD Million) 2021-2034
8.1. Small Molecules
8.2. Large Molecules
8.2.1. Cell & Gene Therapy
8.2.1. CAR T-cell therapies
8.2.1. CAR-NK cell therapy
8.2.1. TCR-T cell therapy
8.2.1. Other
8.2.2. RNA Therapy
8.2.3. Others
9. Global In Vivo CRO Market, By Indication (USD Million) 2021-2034
9.1. Oncology
9.1.1. Blood cancer
9.1.2. Solid tumor
9.1.3. Others
9.2. CNS Conditions
9.2.1. Epilepsy
9.2.2. Parkinson's disease
9.2.3. Huntington's disease
9.2.4. Stroke
9.2.5. Muscular Dystrophy
9.2.6. Alzheimer’s Disease
9.2.7. Traumatic brain injury
9.2.8. Amyotrophic lateral sclerosis (ALS)
9.2.9. Spinal Muscular Atrophy
9.2.10. Muscle regeneration
9.2.11. Other Neurodevelopment Disorders
9.3. Diabetes
9.4. Obesity
9.5. Pain management
9.5.1. Chronic pain
9.5.2. Acute pain
9.6. Autoimmune/inflammation conditions
9.6.1. Rheumatoid Arthritis
9.6.2. Multiple Sclerosis
9.6.3. Osteoarthritis
9.6.4. Irritable Bowel Syndrome
9.6.5. Others
9.7. Others
10. Global In Vivo CRO Market, (USD Million) 2021-2034
10.1. Global In Vivo CRO Market Size and Market Share
11. Global In Vivo CRO Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia
11.1.2. China
11.1.3. India
11.1.4. Japan
11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France
11.2.2. Germany
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia
11.3.2. United Arab Emirates
11.3.3. Qatar
11.3.4. South Africa
11.3.5. Egypt
11.3.6. Morocco
11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada
11.4.2. Mexico
11.4.3. United States
11.5. Latin America
11.5.1. Argentina
11.5.2. Brazil
11.5.3. Rest of Latin America
12. Company Profile
12.1. IQVIA Inc
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Crown Bioscience
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Taconic Biosciences, Inc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. PsychoGenics Inc
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Evotec
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Janvier Labs
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Biocytogen
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. GemPharmatech
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Charles River Laboratories
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Icon Plc
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us